Sequence variation in SCCmec–orfX junction linked to CRISPR-Cas systems disrupts primer binding in rapid molecular assays, causing false-negative MRSA detection
Healthcare settings including hospitals with bloodstream infection cases
Key Highlights
Rapid PCR assays (Xpert, BCID2) detect MRSA via mecA and SCCmec or SCCmec–orfX junction sequences but can miss variants with sequence alterations.
CRISPR-Cas–associated SCCmec variants in MRSA disrupt assay primer binding, leading to false-negative results and misdiagnosis.
These variants, although currently infrequent (~2% of screened MRSA), circulate in healthcare settings and pose a threat to diagnostic accuracy.
Guideline-Based Recommendations
Diagnosis
Be aware of potential false-negative MRSA results from rapid molecular assays due to SCCmec–orfX junction sequence variation.
Consider confirmatory culture and susceptibility testing when rapid assay results are discordant with clinical suspicion.
Implement genomic surveillance to detect emerging SCCmec variants that escape standard molecular detection.
Management
Do not de-escalate empiric anti-MRSA therapy solely based on negative rapid assay results if clinical suspicion remains high.
Adjust antimicrobial therapy based on culture and susceptibility results to ensure effective treatment of MRSA infections.
Monitoring & Follow-up
Monitor for diagnostic failures in rapid MRSA assays and investigate potential variant strains.
Track prevalence and transmission of CRISPR-Cas–associated SCCmec variants within healthcare facilities.
Risks
False-negative MRSA detection may lead to inappropriate antibiotic de-escalation and treatment failure.
Undetected MRSA variants may contribute to ongoing transmission and antimicrobial resistance in healthcare settings.
Patient & Prescribing Data
Patients with suspected or confirmed MRSA bloodstream infections in hospital settings
Empiric vancomycin therapy should be maintained until confirmatory testing rules out MRSA; rapid assay negative results may not exclude resistance due to variant SCCmec elements.
Clinical Best Practices
Use rapid molecular assays as adjuncts but confirm MRSA diagnosis with culture and susceptibility testing.
Maintain high clinical suspicion for MRSA despite negative rapid assay results, especially in hospital-associated lineages like CC5.
Incorporate genomic surveillance to identify and monitor SCCmec variants that evade current diagnostic methods.
Educate clinical teams about limitations of rapid MRSA assays and the potential for diagnostic escape variants.
by Magdalena Podkowik, Alice Tillman, Courtney Takats, Heloise Carion, Gregory Putzel, Julian McWilliams, Benjamin See, Guiqing Wang, Sigridh Munoz-Gomez, Caitlin Otto, Karl Drlica, Luciano Marraffini, Alejandro Pironti, Sarah Hochman, Christopher Kerantzas, Bo Shopsin
The nurse practitioner profession claims the No. 1 spot across three categories in the U.S. News & World Report 2026 Best Jobs rankings for the third consecutive year.
